u/AdEducational82

I recently received the summary statement for my R01 renewal (Competitive - Not Discussed). Significance and Innovation were scored 2–3, and preliminary data was strong, but the overall score was hindered by "modest productivity." This critique overlooks the fact that I inherited the MPI role for only two years. Since then, I’ve published two papers (one as first/corresponding) and generated all the preliminary data in the proposal independently.

I am currently weighing two strategies: Resubmission (A1) vs. New Application (A0). My PO highly suggested an A1 to address the PI transition and technical critiques directly. But my mentor suggested a new submission in June to leverage my ESI status (valid through next April, not affected by previous MPI record) and bypass the "productivity" challenge from the previous cycle.

Questions for the community:

• In the current funding climate, does an A1 with a strong Introduction generally have a higher success rate than a fresh A0? Is it true that reviewers are ignoring prior responsiveness more often this year?
• Is the ESI payline advantage (PO mentioned ~25th percentile for consideration in the past) significant enough to justify abandoning a renewal that already has high conceptual enthusiasm? What's the situation for ESI this year? Is payline still a major factor for funding?
• If I submit an A0 to the same study section (very likely), how do reviewers typically react to a "New" application that is clearly a repackaged renewal? Should I significantly rewrite the title, Aims, or Research Plan to avoid "duplication"?
• Given my publication record: 3 papers in 2026 (one as first/corresponding author) and 5 co-authored in the past five years(including one co-first in NCB), will I still be criticized for productivity as ESI?

Appreciate any insights!

I recently received the summary statement for my first R01 proposal. It was "Competitive - Not Discussed". The criterion scores were relatively strong for Significance/Innovation (2–4), but one reviewer gave an Approach score of 5, citing an “ill-defined” strategy for prioritizing candidate genes and recommending a more rigorous framework for selecting targets for functional validation.

This application was a renewal of a project that I took over as MPI about two years ago, so I was not able to take advantage of my ESI status, which will expire next April. The prior funding period produced two publications over five years, and two reviewers described productivity as “modest” or “minimal.” However, since taking over the project, I have generated the preliminary data highlighted in the application and published a first-author paper this year.

I have a few questions for those with NIH review or program experience:

• How much weight does the “Competitive ND” administrative note typically carry? Does it realistically translate into R56 consideration or select pay, particularly for ESIs?
• Can an Approach concern like "gene prioritization strategy" be fixed in a resubmission?
• What is the best way to frame productivity concerns in this situation, given the recent PI transition? Will this make the reviewers reassess my productivity?
• Would it be more strategic to submit a new A0 application instead of resubmit (A1) to take advantage of ESI eligibility? Do I need to rewrite a proposal for a new application?

I would greatly appreciate any insights or experiences you can share.